Lymphocyte-Depleted Classic HL clinical trials at UCSD
1 in progress, 0 open to eligible people
Sorry, not currently recruiting here
This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
San Diego, California and other locations
Our lead scientists for Lymphocyte-Depleted Classic HL research studies include Carolyn M. Mulroney.